PureTech Health gets FDA Fast Track for MDS drug LYT-200
PureTech Health PLC announced a successful End-of-Phase 1 meeting with the U.S. FDA and receipt of Fast Track designation for its drug LYT-200 in combination with a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.